Literature DB >> 27733628

Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.

Martin J Bobak1, Matthew W Weber1, Melissa A Doellman1, Douglas R Schuweiler1, Jeana M Athens1, Steven A Juliano1, Paul A Garris2.   

Abstract

Modafinil (MOD) exhibits therapeutic efficacy for treating sleep and psychiatric disorders; however, its mechanism is not completely understood. Compared with other psychostimulants inhibiting dopamine (DA) uptake, MOD weakly interacts with the dopamine transporter (DAT) and modestly elevates striatal dialysate DA, suggesting additional targets besides DAT. However, the ability of MOD to induce wakefulness is abolished with DAT knockout, conversely suggesting that DAT is necessary for MOD action. Another psychostimulant target, but one not established for MOD, is activation of phasic DA signaling. This communication mode during which burst firing of DA neurons generates rapid changes in extracellular DA, the so-called DA transients, is critically implicated in reward learning. Here, we investigate MOD effects on phasic DA signaling in the striatum of urethane-anesthetized rats with fast-scan cyclic voltammetry. We found that MOD (30-300 mg/kg i.p.) robustly increases the amplitude of electrically evoked phasic-like DA signals in a time- and dose-dependent fashion, with greater effects in dorsal versus ventral striata. MOD-induced enhancement of these electrically evoked amplitudes was mediated preferentially by increased DA release compared with decreased DA uptake. Principal component regression of nonelectrically evoked recordings revealed negligible changes in basal DA with high-dose MOD (300 mg/kg i.p.). Finally, in the presence of the D2 DA antagonist, raclopride, low-dose MOD (30 mg/kg i.p.) robustly elicited DA transients in dorsal and ventral striata. Taken together, these results suggest that activation of phasic DA signaling is an important mechanism underlying the clinical efficacy of MOD.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27733628      PMCID: PMC5118647          DOI: 10.1124/jpet.116.236000

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  78 in total

Review 1.  The neurobiology of sleep: genetics, cellular physiology and subcortical networks.

Authors:  Edward F Pace-Schott; J Allan Hobson
Journal:  Nat Rev Neurosci       Date:  2002-08       Impact factor: 34.870

2.  Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers.

Authors:  L Ferraro; T Antonelli; W T O'Connor; S Tanganelli; F A Rambert; K Fuxe
Journal:  Biol Psychiatry       Date:  1997-12-15       Impact factor: 13.382

Review 3.  A neural substrate of prediction and reward.

Authors:  W Schultz; P Dayan; P R Montague
Journal:  Science       Date:  1997-03-14       Impact factor: 47.728

4.  Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea.

Authors:  A I Pack; J E Black; J R Schwartz; J K Matheson
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

5.  Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors.

Authors:  W X Shi; C L Pun; X X Zhang; M D Jones; B S Bunney
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

6.  Modafinil binds to the dopamine uptake carrier site with low affinity.

Authors:  E Mignot; S Nishino; C Guilleminault; W C Dement
Journal:  Sleep       Date:  1994-08       Impact factor: 5.849

7.  Dopaminergic role in stimulant-induced wakefulness.

Authors:  J P Wisor; S Nishino; I Sora; G H Uhl; E Mignot; D M Edgar
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

8.  Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.

Authors:  R Kuczenski; D S Segal
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

Review 9.  Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review.

Authors:  R M Battleday; A-K Brem
Journal:  Eur Neuropsychopharmacol       Date:  2015-08-20       Impact factor: 4.600

Review 10.  Treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Merrill S Wise; Donna L Arand; R Robert Auger; Stephen N Brooks; Nathaniel F Watson
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

View more
  3 in total

1.  Different adaptations of dopamine release in Nucleus Accumbens shell and core of individual alcohol drinking groups of mice.

Authors:  Yutong Liu; Sarah E Montgomery; Barbara Juarez; Carole Morel; Song Zhang; Yimeng Kong; Erin S Calipari; Eric J Nestler; Lu Zhang; Ming-Hu Han
Journal:  Neuropharmacology       Date:  2020-06-01       Impact factor: 5.250

2.  Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.

Authors:  Alicia J Avelar; Jianjing Cao; Amy Hauck Newman; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 3.  Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder.

Authors:  Gianluigi Tanda; Melinda Hersey; Briana Hempel; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Curr Opin Pharmacol       Date:  2020-09-11       Impact factor: 5.547

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.